Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 9/20 | 0.34 |
| ▸ | DRD4 | P21917 | 3/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | BDKRB1 | P46663 | 2/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14138919 | 0.82 | PRMT5 (0.35) | MCHR1DRD4SIGMAR1BDKRB1PRMT5 | |
| SCHEMBL5007692 | 0.82 | BDKRB1 (0.37) | MCHR1DRD4SIGMAR1DRD2KCNH2 | |
| SCHEMBL5106378 | 0.81 | BDKRB1 (0.36) | MCHR1KCNH2BDKRB1PRMT5WDR77 | |
| SCHEMBL5145168 | 0.81 | BDKRB1 (0.36) | MCHR1KCNH2BDKRB1PRMT5WDR77 | |
| SCHEMBL5097165 | 0.80 | GRM2 (0.34) | MCHR1DRD4SIGMAR1DRD2KCNH2 | |
| SCHEMBL5007698 | 0.79 | SIGMAR1 (0.34) | MCHR1DRD4SIGMAR1DRD2KCNH2 | |
| SCHEMBL5145162 | 0.76 | GRM2 (0.36) | MCHR1KCNH2BDKRB1PRMT5WDR77 | |
| SCHEMBL5001647 | 0.75 | BDKRB1 (0.43) | BDKRB1 | |
| SCHEMBL5001688 | 0.75 | BDKRB1 (0.43) | BDKRB1 | |
| SCHEMBL5001845 | 0.75 | BDKRB1 (0.41) | MCHR1BDKRB1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249106-A1 | 3-(1-((R)-7-((4-fluoropiperidin-1-yl)methyl)-3,4-dihydro-2H-chromen-4-yl)-1H-1,2,3-triazol-4-yl)-2-(4-methylphenylsulfonamido)propanoic acid; chronic pain analgesics; side effect reduction | AMGEN INC. | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249106-A1 | 3-(1-((R)-7-((4-fluoropiperidin-1-yl)methyl)-3,4-dihydro-2H-chromen-4-yl)-1H-1,2,3-triazol-4-yl)-2-(4-methylphenylsulfonamido)propanoic acid; chronic pain analgesics; side effect reduction | BDKRB1, BDKRB2, FPR1 | MCHR1 510/4885DRD4 2617/4885SIGMAR1 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.